It is now recognized that beyond cholesterol storage issues, cardiac inflammation plays a critical role in the development and progression of atherosclerotic cardiovascular disease (ASCVD). In June 2023, the U.S. Food and Drug Administration approved the first anti-inflammatory cardiovascular treatment, indicating a reduction of myocardial infarction, stroke, coronary revascularization and cardiovascular death in adult patients with established ASCVD or multiple risk factors. Please click to view Dr. Canto's perspective on the opportunities with these new clinical developments.